Redhill Biopharma Ltd. (NASDAQ: RDHL)
$0.40
+0.0029 ( +0.72% ) 228.4K
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Market Data
Open
$0.40
Previous close
$0.40
Volume
228.4K
Market cap
$12.89M
Day range
$0.40 - $0.42
52 week range
$0.26 - $3.28
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 2 | Jul 09, 2024 |
6-k | Quarterly Reports | 1 | Jun 06, 2024 |
6-k | Quarterly Reports | 2 | Jun 03, 2024 |
6-k | Quarterly Reports | 2 | May 06, 2024 |
6-k | Quarterly Reports | 2 | Apr 24, 2024 |
20-f | Annual reports | 117 | Apr 08, 2024 |
6-k | Quarterly Reports | 2 | Apr 08, 2024 |
6-k | Quarterly Reports | 1 | Apr 04, 2024 |
6-k | Quarterly Reports | 9 | Apr 03, 2024 |
6-k | Quarterly Reports | 2 | Apr 02, 2024 |